#1 Clinical Trials Search in Europe

Pneumococcal Polysaccharide Serotype 5

This article discusses clinical trials investigating the safety and efficacy of pneumococcal vaccines containing polysaccharide serotype 5, which is an important component in protecting against pneumococcal infections. The trials examine various pneumococcal vaccine formulations in different populations, including healthy adults, children, and those at increased risk of pneumococcal disease. Key aspects studied include immune responses, safety profiles, and comparisons between different vaccine types.

Table of Contents

What is the pneumococcal polysaccharide serotype 5 vaccine?

The pneumococcal polysaccharide serotype 5 vaccine is a component of several pneumococcal vaccines that help protect against infections caused by the Streptococcus pneumoniae bacteria, also known as pneumococcus. This specific serotype targets the type 5 strain of pneumococcus.[1]

Pneumococcal vaccines containing this serotype are available under brand names like Prevnar 13, Prevenar 13, Apexxnar, and Synflorix. These vaccines contain multiple pneumococcal serotypes to provide broad protection against pneumococcal disease.[2]

How does it work?

The vaccine works by stimulating your immune system to produce antibodies against the type 5 pneumococcal bacteria. Specifically, it contains purified parts of the bacterial capsule (polysaccharides) that are conjugated (attached) to a carrier protein. This conjugation helps improve the immune response, especially in young children.[3]

When you receive the vaccine, your body recognizes these bacterial components as foreign and mounts an immune response. This allows your immune system to quickly recognize and fight off pneumococcal type 5 bacteria if you’re exposed to it in the future, preventing infection.

Who should get this vaccine?

Pneumococcal vaccines containing serotype 5 are recommended for:

  • Infants and young children as part of their routine vaccination schedule
  • Adults 65 years and older
  • People with certain medical conditions that increase their risk of pneumococcal disease, such as:
    • Chronic heart, lung, or liver disease
    • Diabetes
    • Weakened immune systems

The specific recommendations may vary depending on your age, health status, and previous pneumococcal vaccination history. Always consult with your healthcare provider to determine if and when you should receive a pneumococcal vaccine.[4]

How is it administered?

Pneumococcal vaccines containing serotype 5 are typically given as an injection into the muscle (intramuscular injection). For infants, it’s usually injected into the thigh muscle. For older children and adults, it’s usually given in the upper arm.

The number of doses and timing can vary based on the specific vaccine and the person’s age and health status. For example, infants may receive multiple doses as part of their primary vaccination series, while adults may only need a single dose.[5]

How effective is it?

Studies have shown that pneumococcal vaccines containing serotype 5 are effective at preventing invasive pneumococcal disease caused by this specific strain. The effectiveness can vary depending on factors like age, overall health, and the presence of other medical conditions.

In clinical trials, these vaccines have demonstrated the ability to stimulate a strong immune response against serotype 5 pneumococcus. This is measured by looking at antibody levels and opsonophagocytic activity (the ability of antibodies to help immune cells engulf and destroy bacteria) in the blood after vaccination.[1]

Is it safe?

Pneumococcal vaccines containing serotype 5 have been extensively studied and are generally considered safe. They have been approved by regulatory agencies like the FDA and EMA after rigorous testing.

However, like all vaccines, they can cause side effects in some people. Most side effects are mild and resolve on their own within a few days. Serious allergic reactions are very rare.[2]

What are the potential side effects?

Common side effects of pneumococcal vaccines may include:

  • Pain, redness, or swelling at the injection site
  • Mild fever
  • Irritability (in children)
  • Fatigue
  • Headache
  • Muscle or joint pain

These side effects are usually mild and go away on their own within a few days. Severe allergic reactions (anaphylaxis) are very rare but can occur with any vaccine. If you experience symptoms of a severe allergic reaction (such as difficulty breathing, rapid heartbeat, or dizziness) after receiving the vaccine, seek medical attention immediately.[5]

Aspect Details
Study Populations Healthy adults, children, adolescents, adults aged 60+, individuals at increased risk of pneumococcal disease
Vaccine Types Various pneumococcal conjugate vaccines (PCVs), pneumococcal polysaccharide vaccine (PPSV23), new vaccine candidates (e.g. V116)
Primary Outcomes Safety profiles, adverse events, immune responses (OPA titers, IgG levels)
Secondary Outcomes Comparison of immune responses between vaccines, persistence of antibodies, cross-reactive immune responses
Study Designs Randomized, controlled, open-label or double-blind trials
Key Measurements Solicited local and systemic reactions, serious adverse events, OPA titers, IgG concentrations, geometric mean fold rises in antibody levels

FAQ

  • What is the main purpose of these clinical trials? The main purpose is to evaluate the safety, tolerability, and immunogenicity (ability to provoke an immune response) of pneumococcal vaccines containing serotype 5 polysaccharide in various populations.
  • What age groups are being studied in these trials? The trials include a range of age groups, from toddlers as young as 11-15 months old to adults aged 60 years and older. Some trials focus specifically on children and adolescents at increased risk of pneumococcal disease.
  • How is the immune response measured in these studies? The immune response is typically measured through blood tests that look at antibody levels, specifically opsonophagocytic activity (OPA) titers and Immunoglobulin G (IgG) concentrations. These indicate how well the body can recognize and fight pneumococcal bacteria.
  • What are some common side effects being monitored? Common side effects being monitored include injection site reactions (like redness, swelling, and pain), as well as systemic events such as fever, decreased appetite, drowsiness, and irritability. The studies also track any serious adverse events.
  • How do these trials compare different pneumococcal vaccines? Some trials directly compare new vaccine candidates to existing vaccines like PPSV23 (23-valent pneumococcal polysaccharide vaccine) or PCV15 (15-valent pneumococcal conjugate vaccine). They compare factors like immune response, safety profiles, and efficacy in different populations.

Ongoing Clinical Trials on Pneumococcal Polysaccharide Serotype 5

  • Study of pneumococcal vaccines in healthy young adults, older adults and people with HIV infection

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on the Effectiveness of Pneumococcal Vaccines PCV13 and PPV23 in Adults with Acute Leukemia or Lymphoma Undergoing Chemotherapy

    Recruiting

    3 1 1 1
    Investigated drugs:
    France

  • Study on Long-Term Kidney Transplant Outcomes in Low-Risk Patients Using Tacrolimus Alone or with Mycophenolate Mofetil

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on the Safety and Immune Response of a 21-Valent Pneumococcal Vaccine in Healthy Infants, Toddlers, Children, and Adolescents

    Not recruiting

    3 1 1
    Investigated drugs:
    Estonia Poland

  • Study on the Safety and Immune Response of V116 Vaccine for Pneumococcal Disease in Adults Aged 50 and Older

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Germany Spain

  • Study on the Best Time for Influenza Vaccine Administration in Adults Aged 60-85 Using Influenza Vaccine and Drug Combination

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on the Safety and Immune Response of a 21-Valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Belgium Czechia Estonia Finland Germany Greece +3

  • Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Bulgaria Croatia Czechia Denmark +15

  • Study on the Safety and Immune Response of V116 Vaccine in Children and Adolescents at Higher Risk for Pneumococcal Disease

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Finland France Poland Spain Sweden

  • Study on Venetoclax and Dexamethasone for Patients with Relapsed and Refractory Multiple Myeloma with Translocation (11;14)

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Denmark

Glossary

  • Pneumococcal polysaccharide serotype 5: A specific type of sugar molecule found on the surface of certain pneumococcal bacteria. It is included in vaccines to help the immune system recognize and fight these bacteria.
  • Opsonophagocytic activity (OPA): A measure of how well antibodies can help immune cells engulf and destroy bacteria. Higher OPA levels generally indicate better protection against pneumococcal infections.
  • Immunoglobulin G (IgG): A type of antibody that plays a crucial role in the immune response against bacterial infections like pneumococcus.
  • Geometric mean titer (GMT): A way of averaging antibody levels across a group of people, used to compare immune responses between different vaccines or populations.
  • Conjugate vaccine: A type of vaccine where the bacterial polysaccharide is chemically linked to a protein carrier, which can improve the immune response, especially in young children.
  • Invasive pneumococcal disease (IPD): A serious infection where pneumococcal bacteria enter normally sterile sites in the body, such as the bloodstream or spinal fluid.
  • Serotype: A distinct variation within a species of bacteria, in this case referring to different types of pneumococcal bacteria identified by their surface polysaccharides.
  • PPSV23: 23-valent pneumococcal polysaccharide vaccine, a vaccine that protects against 23 different serotypes of pneumococcal bacteria.
  • PCV15: 15-valent pneumococcal conjugate vaccine, a vaccine that protects against 15 different serotypes of pneumococcal bacteria using the conjugate technology.
  • Immunogenicity: The ability of a substance, such as a vaccine, to provoke an immune response in the body.

References

  1. http://clinicaltrials.eu/trial-id/2022-501519-15-00
  2. http://clinicaltrials.eu/trial-id/2022-501988-40-00
  3. http://clinicaltrials.eu/trial/study-on-the-v116-vaccine-for-adults-aged-18-64-at-increased-risk-of-pneumococcal-infection/
  4. http://clinicaltrials.eu/trial/study-on-long-term-safety-and-efficacy-of-pegcetacoplan-for-patients-with-c3-glomerulopathy-or-immune-complex-membranoproliferative-glomerulonephritis/
  5. http://clinicaltrials.eu/trial-id/2023-505154-18-00